Drug Trial Radar · NCT06040541
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
604
Planned (sponsor's estimate)
Start
Sep 7, 2023
Primary completion
Dec 31, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Revolution Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Advanced Solid Tumors
Interventions
RMC-9805Drug
Oral Tablets
RMC-6236Drug
Oral Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Up to 3 years
- Dose Limiting ToxicitiesTime frame: 21 days
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Smilow Cancer Hospital (Yale University)
New Haven, Connecticut · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Lee Moffitt Cancer Center
Tampa, Florida · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
NYU Langone
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke Cancer Center
Durham, North Carolina · Recruiting
Carolina BioOncology Institute
Huntersville, North Carolina · Recruiting
The Christ Hospital
Cincinnati, Ohio · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas · Recruiting
University of Texas, MD Anderson Cancer Center
Houston, Texas · Recruiting
START
San Antonio, Texas · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.